REGENXBIO Inc.

RGNX · Nasdaq · United States

Share price · RGNX

$7.26-3.81 (-34.42%) 3M

close as of 2026-11-18 · 24h delayed · vol 702K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RGNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+10.1%

    Nothing announced by RGNX that day or the session before.

  2. 24 Aug 2026-24.9%
  3. 22 Jun 2026+16.3%
  4. 21 May 2026+13.1%

    Nothing announced by RGNX that day or the session before.

  5. 14 May 2026-37.8%
  6. 6 May 2026+10.8%
  7. 9 Mar 2026+20.0%

    Nothing announced by RGNX that day or the session before.

  8. 10 Feb 2026-14.2%
  9. 28 Jan 2026-17.9%
  10. 23 Jan 2026-13.7%

    Nothing announced by RGNX that day or the session before.

Share of unusual movement by asset

For each asset, the share of RGNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
RGX-202
events and moves
1621%
Clemidsogene lanparvovec
events and moves
118%
Surabgene lomparvovec
events and moves
93%
Other company news (earnings, financing, releases naming no asset)—17%
Sessions with no dated event—51%

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
Iduronate-2-sulfatase (IDS)Gene therapy / editing
Mucopolysaccharidosis Type II
Phase 3
VEGF-AGene therapy / editing
Age-Related Macular Degeneration
Phase 2/3
Dystrophin (microdystrophin transgene)Gene therapy / editing
Duchenne Muscular Dystrophy

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Surabgene lomparvovecPhase 2/3AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration …
Est. primary completion 2026-12 · NCT04704921 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
Clemidsogene lanparvovecPhase 3MPS II, Hunter Syndrome (MPS II)
Est. primary completion 2028-04-30 · NCT07236606 · CT.gov ↗
What to watch
June 2028 (1)
Surabgene lomparvovecPhase 2/3Diabetic Retinopathy
Est. primary completion 2028-06 · NCT07592273 · CT.gov ↗
What to watch
December 2028 (1)
Surabgene lomparvovecPhase 2Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Est. primary completion 2028-12 · NCT03999801 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Surabgene lomparvovecPhase 3Neovascular Age-related Macular Degeneration
Est. primary completion 2033-03 · NCT07007065 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 May 2026Topline resultRGX-202RGX-202 pivotal AFFINITY DUCHENNE Phase 3 topline: primary endpoint met
REGENXBIO Inc. · Source ↗
8 February 2026FDA action dateClemidsogene lanparvovecFDA extends PDUFA date for RGX-121 BLA to February 8, 2026
US, FDA · Source ↗
7 February 2026Complete response letterRGX-121FDA issues Complete Response Letter for the RGX-121 BLA in MPS II
US, FDA · REGENXBIO Inc. · Source ↗
9 November 2025FDA action dateClemidsogene lanparvovecPDUFA target action date set for RGX-121
US, FDA · Source ↗
13 May 2025Filing acceptedClemidsogene lanparvovecFDA accepts BLA for RGX-121 in MPS II
US, FDA · Source ↗
13 May 2025Priority reviewClemidsogene lanparvovecFDA grants Priority Review to RGX-121 BLA
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$9.2M$61M$96M+ $155M short-term inv.$41M$39M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$108M$56M$36M+ $69M short-term inv.—-$62M operating cash flowreport ↗
2026-Q1$6.4M$57M$15M+ $135M short-term inv.$90M-$76M operating cash flowreport ↗
2025-Q3$30M$56M$59M+ $215M short-term inv.$62M-$56M operating cash flowreport ↗
2025-Q2$21M$60M$80M+ $244M short-term inv.$71M-$49M operating cash flowreport ↗
2025-Q1$89M$53M$130M+ $138M short-term inv.—$34M operating cash flowreport ↗
2024-Q3$24M$54M$57M+ $199M short-term inv.$60M-$41M operating cash flowreport ↗
2024-Q2$22M$49M$58M+ $233M short-term inv.$53M-$46M operating cash flowreport ↗
2024-Q1$16M$55M$113M+ $226M short-term inv.$63M-$55M operating cash flowreport ↗
2023-Q3$29M$58M$53M+ $249M short-term inv.$62M-$49M operating cash flowreport ↗
2023-Q2$20M$60M$69M+ $251M short-term inv.$72M-$47M operating cash flowreport ↗
2023-Q1$19M$59M$70M+ $262M short-term inv.$67M-$81M operating cash flowreport ↗
2022-Q3$27M$63M$119M+ $264M short-term inv.$75M-$50M operating cash flowreport ↗
2022-Q2$33M$61M$121M+ $282M short-term inv.$68M-$62M operating cash flowreport ↗
2022-Q1$22M$56M$192M+ $202M short-term inv.$77M-$56M operating cash flowreport ↗
2021-Q3$31M$48M$228M+ $111M short-term inv.$58M-$36M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$170M$228M$34M+ $196M short-term inv.$48M-$124M operating cash flowreport ↗

For full-year 2025, REGENXBIO reported revenue of $170.44M, up 104.5% YoY, with R&D spend of $228.3M, up 9.5% YoY. Cash, cash equivalents, and marketable securities were $240.9M at year-end, and the company posted a net loss of $193.9M, or $3.76 per share basic and diluted.

Management expects the year-end cash position to fund operations into early 2027. Pipeline catalysts include topline pivotal data for RGX-202 in Duchenne in early Q2 2026, topline pivotal data for sura-vec subretinal wet AMD in Q4 2026, and first patient dosing in the pivotal diabetic retinopathy study expected Q2 2026, tied to a $100M milestone from AbbVie. The FDA placed clinical holds on RGX-111 and RGX-121 and issued a complete response letter for the RGX-121 BLA; the company plans to engage the FDA on a potential path forward.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$83M$209M$58M+ $177M short-term inv.$57M-$173M operating cash flowreport ↗
2023-FY$90M$232M$35M+ $241M short-term inv.$66M-$218M operating cash flowreport ↗
2022-FY$113M$242M$97M+ $268M short-term inv.$70M-$207M operating cash flowreport ↗
2021-FY$470M$181M$345M+ $112M short-term inv.—$219M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($949K), 5 sales ($940K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-01Chan Mitchell · Chief Financial OfficerAward / grant24,305——Form 4
2026-11-01PAKOLA STEVE · Chief Medical OfficerAward / grant34,722——Form 4
2026-11-01Christmas Patrick J. · Chief Strategy & Legal OfficerAward / grant34,722——Form 4
2026-11-01Malzahn Craig · Chief Technology OfficerAward / grant27,777——Form 4
2026-09-01Chan Mitchell · Chief Financial OfficerTax withholding4,902$9.32$46KForm 4
2026-09-01Malzahn Craig · Chief Technology OfficerTax withholding234$9.32$2KForm 4
2026-08-27Ciongoli Gregory Austin · directorOpen-market purchase53,407$9.36$500KForm 4
2026-08-26Ciongoli Gregory Austin · directorOpen-market purchase49,196$9.14$450KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 176 reporting institutions held 42.6M shares ($349.7M).

#InstitutionSharesValue
1BlackRock, Inc.5,782,808$48.5M
2Redmile Group, LLC4,368,804$36.6M
3JPMORGAN CHASE & CO3,483,800$27.1M
4STATE STREET CORP2,731,485$22.9M
5MORGAN STANLEY2,066,157$17.3M
6VANGUARD CAPITAL MANAGEMENT LLC2,007,146$16.8M
7GOLDMAN SACHS GROUP INC1,839,463$15.4M
8Integral Health Asset Management, LLC1,500,000$12.6M
9Qube Research & Technologies Ltd1,310,493$11.0M
10GEODE CAPITAL MANAGEMENT, LLC1,137,498$9.5M
11AQR CAPITAL MANAGEMENT LLC1,051,712$8.8M
12VANGUARD PORTFOLIO MANAGEMENT LLC1,018,901$8.5M
13DIMENSIONAL FUND ADVISORS LP1,010,381$8.5M
14Assenagon Asset Management S.A.980,611$8.2M
15Nuveen, LLC582,016$4.9M